In angio-immunoblastogenic T-cell lymphoma (AITL) and peripheral T-cell lymphoma not otherwise specified (PTCL, NOS), the FYN-TRAF3IP2 fusion gene induces aberrant NF-κB signaling downstream of T-cell receptor activation, and inhibition of FYN-TRAF3IP2-induced NF-κB signaling in tumors with an IκB kinase inhibitor provides potent anti-lymphoma effect [100]. This evidence concerns the gene FYN and peripheral T-cell lymphoma, not otherwise specified.